Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Therapy

Background:

• Thymoma, a rare tumor of the thymus, can recur and metastasize, posing treatment challenges.
• Standard chemotherapy may be ineffective for advanced or recurrent thymoma.
• Peptide receptor radionuclide therapy (PRRT) targets somatostatin receptors, often expressed on neuroendocrine tumors, including some thymomas.

Observation:

• A patient with recurrent WHO type A thymoma and pleural metastases, refractory to chemotherapy, was evaluated.
• The thymoma demonstrated positive uptake on In-octreotide imaging, indicating suitability for PRRT.
• The patient received induction and maintenance Lu DOTATATE PRRT, reporting significant symptomatic relief.

Findings:

• Lu DOTATATE PRRT led to notable symptom improvement in this patient with recurrent thymoma.
• Despite initial benefits, mild disease progression was observed before the seventh treatment cycle, leading to therapy cessation.
• This case highlights the potential, yet variable, response of thymoma to Lu DOTATATE PRRT.

Implications:

• The findings suggest that Lu DOTATATE PRRT could be a viable therapeutic option for select patients with recurrent thymoma.
• Further clinical trials are warranted to establish the efficacy, optimal dosing, and long-term outcomes of PRRT in thymoma management.
• This case contributes to the growing body of evidence on the application of PRRT beyond traditional neuroendocrine tumors.